You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Jordan: These 2 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Jordan: These 2 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026" DrugPatentWatch.com thinkBiotech, 2025 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?

Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2025
Generic Entry Controlled by: Jordan Patent 3,492
Patent Title: تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are four patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in forty countries. There has been litigation on patents covering ENTRESTO SPRINKLE

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.

When can LASTACAFT (alcaftadine) generic drug versions launch?

Generic name: alcaftadine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 31, 2026
Generic Entry Controlled by: Jordan Patent 3,358
Patent Title: معالجات حساسية العيون (Ocular Allergy Treatments)

Drug Price Trends for LASTACAFT
LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

Market Analysis and Financial Projection

Jordan's pharmaceutical sector has emerged as a regional leader in branded generics, with exports reaching 85 global markets and contributing 5% to total industrial exports[11]. The industry achieved a 14.8% export growth in 2024 despite regional challenges, totaling JD611 million[11], while maintaining 80% production capacity for international markets[5][9].

Market Assessment

Branded Generics Dominance:

  • Represents 90% of Jordan's pharmaceutical output[7]
  • Key therapeutic areas: Chronic diseases, oncology, and infectious treatments[11]
  • Major exporters: Hikma Pharmaceuticals ($2B global generic sales)[9], JPM, and others serving 85 countries[11]

Export Performance:

  • 19% growth Q1-Q3 2024 (JD437M)[5]
  • Top destinations: Saudi Arabia, Iraq, UAE, and U.S.[5][11]
  • Production capacity: JD1.5B annually across 4,500 products[11]

Supply Chain Dynamics:

  • 70% profit from re-exporting Western drugs[1]
  • Heavy API import dependence (€60-80M annual)[3]
  • Workforce: 7,000 employees (35% female)[11]

Regulatory Opportunities

Accelerated Approvals:

  • 30-60 day fast-track for EMA/USFDA-approved drugs[2][12]
  • Priority registration for first 3 generics[6]
  • GCC harmonization through Central Drug Registration system[2]

Strategic Partnerships:

  • WHO/JFDA collaboration to strengthen PV systems[10]
  • IFC-supported modernization initiative (2023)[5]
  • EMA-aligned quality standards for biosimilars[2][4]

Market Expansion Enablers:

  • Economic Modernisation Vision targets:
    • 20.3% annual export growth through 2033[11]
    • JD1.7B GDP contribution (+217% from 2021)[11]
    • 16,000 pharma jobs by 2033[11]

Key Challenges

Regulatory Hurdles:

  • Fragmented MENA approvals (60+ authorities)[2]
  • Counterfeit drug risks in regional markets[2][6]
  • Compliance costs for USFDA/EU GMP certifications[7]

Market Pressures:

  • Arab neighbors developing domestic production[7]
  • TRIPS agreement impacts from India/Egypt[7]
  • Price harmonization demands in GCC markets[2]

Innovation Gaps:

  • R&D investment <8% of sales[1][7]
  • No originator drug development pipeline[1]
  • Technology limitations in advanced drug forms[3]

Strategic Outlook

The JFDA's new pharmacovigilance framework and digital transformation initiatives position Jordan to capitalize on growing biosimilar demand[4][10]. With 80% production already export-focused, the sector aims to penetrate European markets through WHO benchmarking programs while addressing API dependency via JD1.1B EMV investment targets[11][7]. Success hinges on balancing GCC price controls with innovation incentives in smart packaging and biologics[12][13].

"Our collaboration with WHO ensures Jordan remains the region's pharmacy hub through cutting-edge regulation." - Dr. Nizar Mahidat, JFDA Director[10]

Key statistics:

  • 2024 exports: 19% growth to Saudi Arabia[5]
  • 35% female workforce participation[11]
  • 85 global markets served[11]

References

  1. https://www.giz.de/de/downloads/Value%20Chain%20Analysis%20of%20the%20Pharmaceutical%20Sector%20in%20Jordan.pdf
  2. https://www.delveinsight.com/blog/the-regulatory-process-for-drug-approval-in-the-mena-region
  3. https://aumet.com/en/pharmaceutical-market-in-jordan/
  4. https://www.eminencegroupco.com/ensuring-pharmaceutical-safety-in-jordan/
  5. https://jordantimes.com/news/business/kingdoms-pharmaceutical-industry-grows-19-2024-national-products-reach-80-markets
  6. https://faolex.fao.org/docs/pdf/jor180732E.pdf
  7. https://uiti.org/research/pdf/plc.pdf
  8. https://www.jfda.jo/Pages/viewpage.aspx?pageID=362
  9. https://dai-global-developments.com/articles/now-more-competitive-jordans-pharmaceuticals-see-healthy-jump-in-exports/
  10. https://jordan.un.org/en/260794-who-gov%E2%80%99t-hold-dialogue-strengthen-regulatory-system-enhance-pharmaceutical-production
  11. https://jordantimes.com/news/business/jordans-pharmaceutical-exports-grow-148-2024-overcoming-regional-challenges
  12. https://www.theinsightpartners.com/reports/branded-generics-market
  13. https://credevo.com/articles/2024/02/25/generic-drug-market-in-the-asia-pacific-region-regulations-challenges/
Last updated: 2025-03-19

More… ↓

⤷  Try for Free

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.